1.
European Journal of Hospital Pharmacy Science and Practice
; 30(Suppl 1):A24, 2023.
Article
in English
| ProQuest Central | ID: covidwho-2248825
ABSTRACT
4CPS-004 Figure 1Conclusion and RelevanceThe use of drugs during the pandemic of COVID-19 has shown a clear evolution over months towards more standardised treatments, with remdesivir as antiviral and dexamethasone, tocilizumab and baricitinib standing out as anti-inflammatory drugs in our centre. Homogenisation and standardisation of COVID-19 treatments have been managed as a reflection of the scientific evidence accumulated throughout the pandemic.References and/or AcknowledgementsConflict of InterestNo conflict of interest